Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amunix Pharmaceuticals Inc.

www.amunix.com

Latest From Amunix Pharmaceuticals Inc.

Finance Watch: Multiple VC Mega-Rounds Fund T-Cell, Hearing, IO, Fibrosis Therapies

Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.

Financing StartUps and SMEs

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Deals M & A

Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.

Deals Business Strategies

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Amunix Operating Inc.
  • Amunix Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amunix Pharmaceuticals Inc.
  • Senior Management
  • Angie You, PhD, CEO
    Volker Schellenberger, PhD, Pres. & CTO
    Mika Derynck, MD, CMO
    Darcy Mootz, PhD, CBO
    Yvonne Li, SVP, Fin.
    Bryan Irving, PhD, CSO
  • Contact Info
  • Amunix Pharmaceuticals Inc.
    Phone: (650) 428-1800
    500 Ellis St.
    Mountain View, CA 94043
    USA
UsernamePublicRestriction

Register